drugset / Trial / NCT00501878

2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides

NCT00501878

Phase 4 Completed 100 enrolled Khon Kaen University
RandomizedParallel-groupDouble-blindDiagnostic

Summary

To compare the clinical efficacy and systemic side effects between 2.5% and 10% phenylephrine for mydriasis in diabetic patient with darkly pigmented irides.

Timeline

Start
2007-05
Primary completion
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Phenylephrine Small molecule 2.5 % Topical
Subject Phenylephrine Small molecule 10 % Topical

Indications